Dimethyl fumarate controlled-release - Forward Pharma

Drug Profile

Dimethyl fumarate controlled-release - Forward Pharma

Alternative Names: FP-187

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Forward Pharma
  • Developer Forward Pharma; Skane University Hospital
  • Class Anti-inflammatories; Antipsoriatics; Cytoprotectives; Esters; Fumarates; Small molecules
  • Mechanism of Action NF E2 related factor 2 stimulants; NF-kappa B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Plaque psoriasis; Psoriatic arthritis
  • No development reported Multiple sclerosis

Most Recent Events

  • 17 Jan 2017 Forward Pharma enters into a settlement and license agreement with Biogen related to oral administration of dimethyl fumarate 480mg for multiple sclerosis
  • 08 Aug 2016 Forward Pharma withdraws a phase III trial for Plaque psoriasis in Canada, European Union, Russia and Ukraine prior to enrolment (NCT01815723)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Germany (PO, Controlled release)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top